Two public programs in North Carolina now give opposite answers to the same question, and the question is the most expensive one in American healthcare right now: should the state pay for weight-loss drugs? Medicaid says yes. The State Health Plan, which covers roughly 700,000 teachers, state employees, retirees and their families, says no. The divergence is not an accident of policy. It is a direct consequence of how each program's budget works.
The split sharpened this year. Medicaid's coverage was cut in October 2025, restored by Governor Josh Stein in December, and now faces a legislatively ordered cost-savings plan due in October 2026. The State Health Plan's coverage ended in April 2024 and has not returned, and the July 2026 state budget signed by the governor did not restore it. Same state, same drugs, same legislature. Different checks.
The Medicaid side: coverage as a political lever
North Carolina Medicaid began covering FDA-approved obesity drugs with prior authorization in August 2024. In October 2025 the program dropped obesity-only coverage, citing a state funding shortfall, while keeping coverage for diabetes and cardiovascular uses. The reversal came fast. Stein restored the previous criteria effective December 12, 2025, as part of a broader reversal of Medicaid cuts after lawsuits. The program now requires step therapy: Wegovy is preferred, and members must try it first, or document a medical reason not to, before Zepbound or Saxenda are covered.
The numbers behind the policy fight are substantial. In June 2026, 34,524 Medicaid beneficiaries filed weight-loss GLP-1 claims totaling $47.86 million, about $1,386 per member that month, before federal matching funds and confidential rebates. Medicaid's budget has grown to $41.6 billion, roughly 22 percent of the state's General Fund, from $21.6 billion four years earlier. That growth is why the April 2026 overrun-funding law directed the health department to produce a cost-savings plan that could tie weight-loss drug coverage to mandatory lifestyle and nutrition program participation, with changes barred before July 2027.
The political mechanics are visible in the timeline: a cut made by one administration, restored by another, then sent to a legislative savings process. Medicaid coverage for these drugs is not a settled policy in North Carolina. It is a lever that moves with whoever holds it.
The State Health Plan side: coverage as a budget line
The State Health Plan reached its answer through arithmetic rather than politics, and it has stayed there. The board voted in January 2024 to end weight-loss GLP-1 coverage effective that April, under the prior treasurer. At the time, more than 23,000 members were using the drugs at a net cost above $800 per member per month after rebates. Projections showed spending growing from about $170 million in 2024 toward $1 billion or more by 2030, in a plan already carrying a projected deficit of roughly $500 million next year and $1.5 billion by 2027.
Treasurer Brad Briner, the board's chair, has sought a middle path. He asked the legislature for roughly $100 million to cover about 14,000 members with a body mass index of 38 or above, a group he described as "populations that really have obesity problems." The Senate offered $25 million. The House offered nothing. The final budget included nothing, and Briner's own assessment before it passed was resigned, as WRAL reported: he had hoped it would get there that year, but did not think it likely.
The plan did get one new tool. An October 2025 contract change with its pharmacy benefit manager lets the plan negotiate directly with the drugmakers, and Briner has called those talks promising while insisting "current prices remain unaffordable given the Plan's financial condition," in the words of his office. A $100 million carve-out for the most severe cases remains the plan's ask, and the legislature remains the obstacle.
The structural difference
The two programs diverge because their money has different owners. Medicaid is funded by the General Fund and the federal government, so covering the drugs spends someone else's shared pool, and the political cost lands on whoever cuts. The State Health Plan is funded by employer and member premiums and the state's contributions, and its board answers for its own balance sheet, so the fiscal cost lands on the people who approve the coverage. One program can spend politically. The other must spend actuarially.
That structural difference explains the identical framing used by both sides of the argument, in opposite directions. Cost controllers point to the plan's deficit and to the Medicaid overrun law. Treatment advocates, including the Obesity Action Coalition and obesity-medicine physicians, argue the state pays for obesity's consequences, diabetes, joint replacements, cardiac events, while denying its treatment, and that patients with low incomes and public employees have no out-of-pocket alternative. Both arguments are true. They are true in different programs because the programs run on different ledgers.
The national pattern
North Carolina is not diverging from the country. It is showing the country's full range within one state. Federal law has barred Medicare Part D from covering weight-loss drugs since 2003, and a Biden-era proposal to change that was never finalized. The CMS "Bridge" demonstration now offers them at about $50 a month for eligible Medicare patients through 2027, but that is a demonstration, not a benefit. Large-employer coverage of obesity drugs fell from 72 percent of plans in 2025 to 60 percent in 2026, with Starbucks ending coverage in October and Bank of America retaining it at a cost above $250 million a year. California's Medi-Cal dropped the drugs in January 2026; Massachusetts will end coverage in July, affecting roughly 22,000 people.
The North Carolina example matters because it makes the mechanism legible. When the drug's price exceeds what a budget can bear, the coverage decision follows the budget's owner. Medicaid in North Carolina covers these drugs because the General Fund absorbed the choice. Teachers do not get them because their plan's board cannot print money and the legislature chose not to send any. Every future coverage fight over this drug class, in any state, is a version of this same question: whose money is it?
Primary sources
- North Carolina DHHS bulletin for the Medicaid restoration and step-therapy criteria.
- Carolina Journal for the June 2026 claims data and the diverging strategies.
- WRAL for the State Health Plan budget history and Briner's statements.
- BPR for the pharmacy benefit manager contract change and the negotiation posture.
- Medicare Rights Center for the CMS Bridge demonstration parameters.
- Marketplace and Insurance Business Magazine for national employer coverage trends.